<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36148046</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2474-0896</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>British journal of biomedical science</Title><ISOAbbreviation>Br J Biomed Sci</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 and COVID-19: A Narrative Review.</ArticleTitle><Pagination><StartPage>10426</StartPage><MedlinePgn>10426</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">10426</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/bjbs.2022.10426</ELocationID><Abstract><AbstractText>The World Health Organisation has reported that the viral disease known as COVID-19, caused by SARS-CoV-2, is the leading cause of death by a single infectious agent. This narrative review examines certain components of the pandemic: its origins, early clinical data, global and UK-focussed epidemiology, vaccination, variants, and long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Blann and Heitmar.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blann</LastName><ForeName>A D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>School of Applied Sciences, University of Huddersfield Queensgate, Huddersfield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heitmar</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Applied Sciences, University of Huddersfield Queensgate, Huddersfield, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Br J Biomed Sci</MedlineTA><NlmUniqueID>9309208</NlmUniqueID><ISSNLinking>0967-4845</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword><Keyword MajorTopicYN="N">variants</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>2</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36148046</ArticleId><ArticleId IdType="pmc">PMC9486701</ArticleId><ArticleId IdType="doi">10.3389/bjbs.2022.10426</ArticleId><ArticleId IdType="pii">10426</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Salvamani S, Tan HZ, Thang WJ, Ter HC, Wan MS, Gunasekaran B, et al. Understanding the Dynamics of COVID-19; Implications for Therapeutic Intervention, Vaccine Development and Movement Control. Br J Biomed Sci (2020) 77:168&#x2013;84. 10.1080/09674845.2020.1826136</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09674845.2020.1826136</ArticleId><ArticleId IdType="pubmed">32942955</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organisation. Covid-19 Dashboard (2019). https://www.who.int/emergencies/diseases/novel-coronavirus-2019
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>
World Health Organisation. World Health Organisation Report on the SARS-CoV-1 Outbreak (2015). https://www.who.int/publications/m/item/summary-of-probable-sars-cases-with-onset-of-illness-from-1-november-2002-to-31-july-2003
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med (2020) 382:727&#x2013;33. 10.1056/NEJMoa2001017</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JF, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic Characterization of the 2019 Novel Human-Pathogenic Coronavirus Isolated from a Patient with Atypical Pneumonia after Visiting Wuhan. Emerg Microbes Infect (2020) 9:221&#x2013;36. 10.1080/22221751.2020.1719902</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1719902</ArticleId><ArticleId IdType="pmc">PMC7067204</ArticleId><ArticleId IdType="pubmed">31987001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding. Lancet (2020) 395:565&#x2013;74. 10.1016/S0140-6736(20)30251-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30251-8</ArticleId><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Library of Medicine. Search for &#x201c;SARS-Cov-2&#x201d;. 
https://www.ncbi.nlm.nih.gov/nuccore/?term=SARS-Cov-2 (Accessed May 12, 2022). </Citation></Reference><Reference><Citation>
GISAID. 
https://www.gisaid.org/ (Accessed May 12, 2022).</Citation></Reference><Reference><Citation>Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature (2020) 579:270&#x2013;3. 10.1038/s41586-020-2012-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The Species Severe Acute Respiratory Syndrome-Related Coronavirus: Classifying 2019-nCoV and Naming it SARS-CoV-2. Nat Microbiol (2020) 5:536&#x2013;44. 10.1038/s41564-020-0695-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0695-z</ArticleId><ArticleId IdType="pmc">PMC7095448</ArticleId><ArticleId IdType="pubmed">32123347</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organisation. Novel Coronavirus (2019-nCoV) SITUATION REPORT - 1 (2020). https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>
World Health Organisation. Coronavirus Disease 2019 (COVID-19) Situation Report &#x2013; 23 (2020). https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200212-sitrep-23-ncov.pdf?sfvrsn=41e9fb78_4
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing SARS-CoV-2 with SARS-CoV and Influenza Pandemics. Lancet Infect Dis (2020) 20:e238&#x2013;e244. 10.1016/S1473-3099(20)30484-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30484-9</ArticleId><ArticleId IdType="pmc">PMC7333991</ArticleId><ArticleId IdType="pubmed">32628905</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: a Descriptive Study.. Lancet (2020) 395:507&#x2013;13. 10.1016/S0140-6736(20)30211-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.. J Amer Med Assoc (2020) 323:1061&#x2013;9. 10.1001/jama.2020.1585</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Zhu C, Yang L, Dong H, Wang R, Ni H, et al. Identification of Risk Factors for Mortality Associated with COVID-19. PeerJ (2020) 8:e9885. 10.7717/peerj.9885</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.9885</ArticleId><ArticleId IdType="pmc">PMC7473053</ArticleId><ArticleId IdType="pubmed">32953279</ArticleId></ArticleIdList></Reference><Reference><Citation>Canevelli M, Palmieri L, Raparelli V, Punzo O, Donfrancesco C, Lo Noce C, et al. COVID-19 Mortality Among Migrants Living in Italy. Ann Ist Super Sanit&#xe0; (2020) 56:373&#x2013;7. 10.4415/ANN_20_03_16</Citation><ArticleIdList><ArticleId IdType="doi">10.4415/ANN_20_03_16</ArticleId><ArticleId IdType="pubmed">32959804</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi PG, Marino M, Formisano D, et al. Characteristics and Outcomes of a Cohort of COVID-19 Patients in the Province of Reggio Emilia. Italy Plos ONE (2020) 15(8):e0238281. 10.1371/journal.pone.0238281</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0238281</ArticleId><ArticleId IdType="pmc">PMC7451640</ArticleId><ArticleId IdType="pubmed">32853230</ArticleId></ArticleIdList></Reference><Reference><Citation>Estella A, Garcia Garmendia JL, de la Fuente C, Machado Casas JF, Yuste ME, Amaya Villar R, et al. Predictive Factors of Six-Week Mortality in Critically Ill Patients with SARS-CoV-2: A Multicenter Prospective Study. Med Intensiva (Engl Ed (2021) 46:179&#x2013;91. 10.1016/j.medin.2021.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medin.2021.02.013</ArticleId><ArticleId IdType="pmc">PMC7938739</ArticleId><ArticleId IdType="pubmed">33812670</ArticleId></ArticleIdList></Reference><Reference><Citation>Poll&#xe1;n M, P&#xe9;rez-G&#xf3;mez B, Pastor-Barriuso R, Oteo J, Hernan MA, Perez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a Nationwide, Population-Based Seroepidemiological Study. Lancet (2020) 396:535&#x2013;44. 10.1016/S0140-6736(20)31483-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31483-5</ArticleId><ArticleId IdType="pmc">PMC7336131</ArticleId><ArticleId IdType="pubmed">32645347</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano V, Barreiro P. Why Such Excess of Mortality for COVID-19 in Spain? Ther Adv Infect Dis (2020) 7:2049936120932755. 10.1177/2049936120932755</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2049936120932755</ArticleId><ArticleId IdType="pmc">PMC7273618</ArticleId><ArticleId IdType="pubmed">32547741</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenton NE, Neil M, Osman M, McLachlan S. COVID-19 Infection and Death Rates: the Need to Incorporate Causal Explanations for the Data and Avoid Bias in Testing. J Risk Res (2020) 23:862&#x2013;5. 10.1080/13669877.2020.1756381</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13669877.2020.1756381</ArticleId></ArticleIdList></Reference><Reference><Citation>Boin A, Lodge M, Luesink M. Learning from the COVID-19 Crisis: an Initial Analysis of National Responses. Policy Des Pract (2020) 33:189&#x2013;204. 10.1080/25741292.2020.1823670</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/25741292.2020.1823670</ArticleId></ArticleIdList></Reference><Reference><Citation>Capano G, Howlett M, Jarvis DSL, Ramesh M, Goyal N. Mobilizing Policy (In)Capacity to Fight COVID-19: Understanding Variations in State Responses.. Policy Soc (2020) 39:285&#x2013;308. 10.1080/14494035.2020.1787628</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14494035.2020.1787628</ArticleId><ArticleId IdType="pmc">PMC8754710</ArticleId><ArticleId IdType="pubmed">35039722</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapitany-Foveny M, Sulyok M. Social Markers of a Pandemic: Modelling the Association between Cultural Norms Land COVID-19 Spread Data. Hum Soc Sci Comms (2020) 7:97. 10.1057/s41599-020-00590-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1057/s41599-020-00590-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh D, Cunningham AC. Counting Coronavirus Disease 2019 (COVID-19) Cases: Case Definitions, Screened Populations and Testing Techniques Matter. Ann Acad Med Singap (2020) 49:161&#x2013;5. 10.47102/annals-acadmedsg.202038</Citation><ArticleIdList><ArticleId IdType="doi">10.47102/annals-acadmedsg.202038</ArticleId><ArticleId IdType="pubmed">32301478</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang TK, Wu P, Lin Y, Lau EHY, Leung GM, Cowling BJ. Effect of Changing Case Definitions for COVID-19 on the Epidemic Curve and Transmission Parameters in mainland China: a Modelling Study. Lancet Public Health (2020) 5:e289&#x2013;e296. 10.1016/S2468-2667(20)30089-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(20)30089-X</ArticleId><ArticleId IdType="pmc">PMC7173814</ArticleId><ArticleId IdType="pubmed">32330458</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan RE, Adab P, Cheng KK. Covid-19: Risk Factors for Severe Disease and Death. Br Med J (2020) 368:m1198. 10.1136/bmj.m1198</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1198</ArticleId><ArticleId IdType="pubmed">32217618</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon JJ, Heyman B, Ko JP, Condos R, Lynch DA. CT of Post-Acute Lung Complications of COVID-19. Radiology (2021) 301:E383&#x2013;E395. 10.1148/radiol.2021211396</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021211396</ArticleId><ArticleId IdType="pmc">PMC8369881</ArticleId><ArticleId IdType="pubmed">34374591</ArticleId></ArticleIdList></Reference><Reference><Citation>Dillon K, Hook C, Coupland Z, Avery P, Taylor H, Lockyer A. Pre-hospital Lowest Recorded Oxygen Saturation Independently Predicts Death in Patients with COVID-19. Br Paramed J (2020) 5:59&#x2013;65. 10.29045/14784726.2020.09.5.3.59</Citation><ArticleIdList><ArticleId IdType="doi">10.29045/14784726.2020.09.5.3.59</ArticleId><ArticleId IdType="pmc">PMC7783956</ArticleId><ArticleId IdType="pubmed">33456398</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, et al. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. Am J Respir Crit Care Med (2020) 202(12):1656&#x2013;65. 10.1164/rccm.202007-2794OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202007-2794OC</ArticleId><ArticleId IdType="pmc">PMC7737581</ArticleId><ArticleId IdType="pubmed">33007173</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, et al. Six-month Follow-Up Chest CT Findings after Severe COVID-19 Pneumonia. Radiology (2021) 299:E177&#x2013;E186. 10.1148/radiol.2021203153</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021203153</ArticleId><ArticleId IdType="pmc">PMC7841877</ArticleId><ArticleId IdType="pubmed">33497317</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva Andrade B, Siqueira S, de Assis Soares WR, de Souza Rangel F, Santos NO, Dos Santos Freitas A, et al. Long-COVID and Post-COVID Health Complications: An Up-To-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. Viruses (2021) 13:700. 10.3390/v13040700</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13040700</ArticleId><ArticleId IdType="pmc">PMC8072585</ArticleId><ArticleId IdType="pubmed">33919537</ArticleId></ArticleIdList></Reference><Reference><Citation>Wathen CG, Sudlow MF. Pneumonia. Postgrad Med J (1986) 62:396&#x2013;76. 10.1136/pgmj.62.727.369</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/pgmj.62.727.369</ArticleId><ArticleId IdType="pmc">PMC2418683</ArticleId><ArticleId IdType="pubmed">3532084</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara JL, Abhyankar S, Gilliland DG. Cytokine Storm of Graft Versus-Host Disease: a Critical Effector Role for Interleukin-1. Transpl Proc (1993) 25:1216&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8442093</ArticleId></ArticleIdList></Reference><Reference><Citation>Samson SY, Wong KY. The Severe Acute Respiratory Syndrome (SARS). J Neurovirol (2005) 11:455&#x2013;68. 10.1080/13550280500187724</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13550280500187724</ArticleId><ArticleId IdType="pmc">PMC7095431</ArticleId><ArticleId IdType="pubmed">16287687</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the Eye of the Cytokine Storm. Microbiol Mol Biol Rev (2012) 76:16&#x2013;32. 10.1128/MMBR.05015-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MMBR.05015-11</ArticleId><ArticleId IdType="pmc">PMC3294426</ArticleId><ArticleId IdType="pubmed">22390970</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrens EM, Koretzky GA. Review: Cytokine Storm Syndrome: Looking toward the Precision Medicine Era. Arthritis Rheumatol (2017) 69:1135&#x2013;43. 10.1002/art.40071</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40071</ArticleId><ArticleId IdType="pubmed">28217930</ArticleId></ArticleIdList></Reference><Reference><Citation>Comer SP, Cullivan S, Szklanna PB, Weiss L, Cullen S, Kelliher S, et al. COVID-19 Induces a Hyperactive Phenotype in Circulating Platelets. Plos Biol (2021) 19:e3001109. 10.1371/journal.pbio.3001109</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001109</ArticleId><ArticleId IdType="pmc">PMC7920383</ArticleId><ArticleId IdType="pubmed">33596198</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Zhang Y, Qia W, Zhang J, Qi Z. Baricitinib, a Drug with Potential Effect to Prevent SARS-COV-2 from Entering Target Cells and Control Cytokine Storm Induced by COVID-19. Int Immunopharmacol (2020) 86:106749. 10.1016/j.intimp.2020.106749</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.106749</ArticleId><ArticleId IdType="pmc">PMC7328558</ArticleId><ArticleId IdType="pubmed">32645632</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-Of-The-Art Review.. J Am Coll Cardiol (2020) 75:2950&#x2013;73. 10.1016/j.jacc.2020.04.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.04.031</ArticleId><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber GF, Chaturvedi S. How to Recognize and Manage COVID-19-Associated Coagulopathy. Hematol Am Soc Hematol Educ Program (2021) 2021(1):614&#x2013;20. 10.1182/hematology.2021000297</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/hematology.2021000297</ArticleId><ArticleId IdType="pmc">PMC8791093</ArticleId><ArticleId IdType="pubmed">34889412</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos AC, Bonaca MP. Studying the Coagulopathy of COVID-19. Lancet (2022) 399(21):118&#x2013;9. 10.1016/S0140-6736(21)01906-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01906-1</ArticleId><ArticleId IdType="pmc">PMC8598181</ArticleId><ArticleId IdType="pubmed">34800425</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of Thrombotic Complications in Critically Ill ICU Patients with COVID-19. Thromb Res (2020) 191:145&#x2013;7. 10.1016/j.thromres.2020.04.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.04.013</ArticleId><ArticleId IdType="pmc">PMC7146714</ArticleId><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, et al. Endotheliopathy in COVID-19-Associated Coagulopathy: Evidence from a single-centre, Cross-Sectional Study. Lancet Haematol (2020) 7:e575&#x2013;e582. 10.1016/S2352-3026(20)30216-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30216-7</ArticleId><ArticleId IdType="pmc">PMC7326446</ArticleId><ArticleId IdType="pubmed">32619411</ArticleId></ArticleIdList></Reference><Reference><Citation>Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost (2006) 95:49&#x2013;55. 10.1160/th05-07-0527</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/th05-07-0527</ArticleId><ArticleId IdType="pubmed">16543961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, et al. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromb Haemost (2020) 120:1004&#x2013;24. 10.1055/s-0040-1713152</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1713152</ArticleId><ArticleId IdType="pmc">PMC7516364</ArticleId><ArticleId IdType="pubmed">32473596</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY collaborative group. Aspirin in Patients Admitted to Hospital with COVID-19 (RECOVERY): a Randomised, Controlled, Open-Label, Platform Trial. Lancet (2022) 399:143&#x2013;51. 10.1016/S0140-6736(21)01825-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01825-0</ArticleId><ArticleId IdType="pmc">PMC8598213</ArticleId><ArticleId IdType="pubmed">34800427</ArticleId></ArticleIdList></Reference><Reference><Citation>Clift AK, Coupland CAC, Keogh RH, Diaz-Ordaz K, Williamson E, Harrison EM, et al. Living Risk Prediction Algorithm (QCOVID) for Risk of Hospital Admission and Mortality from Coronavirus 19 in Adults: National Derivation and Validation Cohort Study. BMJ (2020) 371:m3731. 10.1136/bmj.m3731</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3731</ArticleId><ArticleId IdType="pmc">PMC7574532</ArticleId><ArticleId IdType="pubmed">33082154</ArticleId></ArticleIdList></Reference><Reference><Citation>
NHS. Coronavirus (COVID-19) Risk Assessment (2021). 
https://digital.nhs.uk/coronavirus/risk-assessment (Accessed May 12, 2022). </Citation></Reference><Reference><Citation>McIntyre PB, Aggarwal R, Jani I, Jawad J, Kochhar S, MacDonald N, et al. COVID-19 Vaccine Strategies Must Focus on Severe Disease and Global Equity. Lancet (2022) 399:406&#x2013;10. 10.1016/S0140-6736(21)02835-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02835-X</ArticleId><ArticleId IdType="pmc">PMC8676417</ArticleId><ArticleId IdType="pubmed">34922639</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliu-Barton M, Pradelski BSR, Algan Y, Baker MG, Binagwaho A, Dore GJ, et al. Elimination versus Mitigation of SARS-CoV-2 in the Presence of Effective Vaccines. Lancet Glob Health (2022) 10:e142&#x2013;e147. 10.1016/S2214-109X(21)00494-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(21)00494-0</ArticleId><ArticleId IdType="pmc">PMC8563003</ArticleId><ArticleId IdType="pubmed">34739862</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips N. The Coronavirus Is Here to Stay &#x2013; Here&#x2019;s what that Means. Nature (2021) 590:382&#x2013;4. 10.1038/d41586-021-00396-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-00396-2</ArticleId><ArticleId IdType="pubmed">33594289</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray CJL, Piot P. The Potential Future of the COVID-19 Pandemic. Will SARS-CoV-2 Become a Recurrent Seasonal Infection? J Amer Med Assoc (2021) 325:1249&#x2013;50. 10.1001/jama.2021.2828</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.2828</ArticleId><ArticleId IdType="pubmed">33656519</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricke-Galindo I, Falfan-Valencia R. Genetics Insight for COVID-19 Susceptibility and Severity: a Review. Front Immunol (2021) 12:622176. 10.3389/fimmu.2021.622176</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.622176</ArticleId><ArticleId IdType="pmc">PMC8047200</ArticleId><ArticleId IdType="pubmed">33868239</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med (2021) 384:693&#x2013;704. 10.1056/nejmoa2021436</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Tocilizumab in Patients Admitted to Hospital with COVID-19 (RECOVERY). Lancet (2021) 397:1637&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: Molnupiravir Reduces Risk of Hospital Admission or Death by 50% in Patients at Risk, MSD Reports. Br Med J BMJ (2021) 375:n2422. 10.1136/bmj.n2422</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2422</ArticleId><ArticleId IdType="pubmed">34607801</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G, Dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, et al. Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalisation Among Patients with COVID-19: the TOGETHER Randomised, Platform Clinical Trial. Lancet Glob Health (2021) 10(21):e4200448&#x2013;514. 10.1016/S2214-109X(21)00448-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(21)00448-4</ArticleId><ArticleId IdType="pmc">PMC8550952</ArticleId><ArticleId IdType="pubmed">34717820</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organisation. The World Health Organisation Document: COVID-19 Clinical Management: Living Guidance (2021). https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>
The National Institute for Health and Care Excellence (NICE). COVID-19 Rapid Guidelines: Managing COVID-19 (NG191) (2022). https://www.nice.org.uk/search?q=NG191
(Accessed May 12, 2022). </Citation><ArticleIdList><ArticleId IdType="pubmed">34181371</ArticleId></ArticleIdList></Reference><Reference><Citation>Couzin-Frankel J. Antiviral Pills Could Change Pandemic&#x2019;s Course. Science (2021) 374:799&#x2013;800. 10.1126/science.acx9605</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.acx9605</ArticleId><ArticleId IdType="pubmed">34762459</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, et al. SARS-CoV-2-neutralising Monoclonal Antibodies for Treatment of COVID-19. Cochrane Database Syst Rev (2021) 9(9):CD013825. 10.1002/14651858.CD013825.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013825.pub2</ArticleId><ArticleId IdType="pmc">PMC8411904</ArticleId><ArticleId IdType="pubmed">34473343</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemieniuk RA, Bartoszko JJ, D&#xed;az Martinez JP, Kum E, Qasim A, Zeraatkar D, et al. Antibody and Cellular Therapies for Treatment of Covid-19: a Living Systematic Review and Network Meta-Analysis. BMJ (2021) 374:n2231. 10.1136/bmj.n2231</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2231</ArticleId><ArticleId IdType="pmc">PMC8459162</ArticleId><ArticleId IdType="pubmed">34556486</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Rodrigues Falci D, et al. Effect of Sotrovimab on Hospitalisation or Death Among High-Risk Patients with Mild to Moderate COVID-19. J Amer Med Assoc (2022) 327:1236&#x2013;46. 10.1001/jama.2022.2832</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.2832</ArticleId><ArticleId IdType="pmc">PMC8922199</ArticleId><ArticleId IdType="pubmed">35285853</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab on Viral Load in Patients with Mild to Moderate COVID-19: A Randomized Clinical Trial. J Amer Med Assoc (2021) 325:632&#x2013;44. 10.1001/jama.2021.0202</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.0202</ArticleId><ArticleId IdType="pmc">PMC7821080</ArticleId><ArticleId IdType="pubmed">33475701</ArticleId></ArticleIdList></Reference><Reference><Citation>
NHS. Treatments for Coronavirus (COVID-19) (2022). https://www.nhs.uk/conditions/coronavirus-covid-19/treatments-for-coronavirus/
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>
COVID-19 Vaccine Tracker. 
https://www.covid-19vaccinetracker.org/authorized-vaccines (Accessed May 12, 2022).</Citation></Reference><Reference><Citation>Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) against SARS-CoV-2: an Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK. Lancet (2021) 397:99&#x2013;111. 10.1016/S0140-6736(20)32661-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SJ, Moreira ED, Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med (2021) 385:3851761&#x2013;1773. 10.1056/NEJMoa2110345</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110345</ArticleId><ArticleId IdType="pmc">PMC8461570</ArticleId><ArticleId IdType="pubmed">34525277</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med Overseas Ed (2021) 384:403&#x2013;16. 10.1056/nejmoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghazy RM, Ashmawy R, Hamdy NA, Elhadi YAM, Reyad OA, Elmalawany D, et al. Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. Vaccines (2022) 10:350. 10.3390/vaccines10030350</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10030350</ArticleId><ArticleId IdType="pmc">PMC8948677</ArticleId><ArticleId IdType="pubmed">35334982</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YZ, Kuan CC. Vaccination to Reduce Severe COVID-19 and Mortality in COVID-19 Patients: a Systematic Review and Meta-Analysis. Eur Rev Med Pharmacol Sci (2022) 26:1770&#x2013;6. 10.26355/eurrev_202203_28248</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202203_28248</ArticleId><ArticleId IdType="pubmed">35302230</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed I, Nauman A, Paul P, Ganesan S, Chen KH, Jalil SMS, et al. The Efficacy and Effectiveness of the COVID-19 Vaccines in Reducing Infection, Severity, Hospitalization, and Mortality: a Systematic Review. Hum Vaccin Immunother (2022) 18:2027160&#x2013;20. 10.1080/21645515.2022.2027160</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2027160</ArticleId><ArticleId IdType="pmc">PMC8862168</ArticleId><ArticleId IdType="pubmed">35113777</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Boyton RJ. COVID-19 Vaccination: The Road Ahead. Science (2022) 375:1127&#x2013;32. 10.1126/science.abn1755</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn1755</ArticleId><ArticleId IdType="pubmed">35271316</ArticleId></ArticleIdList></Reference><Reference><Citation>Klamer TA, Linschoten M, Asselbergs FW. The Benefit of Vaccination against COVID-19 Outweighs the Potential Risk of Myocarditis and Pericarditis. Neth Heart J (2022) 30:190&#x2013;7. 10.1007/s12471-022-01677-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12471-022-01677-9</ArticleId><ArticleId IdType="pmc">PMC8906525</ArticleId><ArticleId IdType="pubmed">35266090</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T, Levy JH. Thrombosis and Thrombocytopenia in COVID-19 and after COVID-19 Vaccination. Trends Cardiovasc Med (2022) 32:249&#x2013;25. 10.1016/j.tcm.2022.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2022.02.008</ArticleId><ArticleId IdType="pmc">PMC8861143</ArticleId><ArticleId IdType="pubmed">35202800</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceacareanu AC, Wintrob ZAP. Summary of COVID-19 Vaccine-Related Reports in the Vaccine Adverse Event Reporting System. J Res Pharm Pract (2021) 10:107&#x2013;13. 10.4103/jrpp.jrpp_49_21</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jrpp.jrpp_49_21</ArticleId><ArticleId IdType="pmc">PMC8809454</ArticleId><ArticleId IdType="pubmed">35198503</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiese A, Baronti A, Manetti AC, Di Paolo M, Turillazzi E, Frati P, et al. Death after the Administration of COVID-19 Vaccines Approved by EMA: Has a Causal Relationship Been Demonstrated? Vaccines (2022) 10(2):308. 10.3390/vaccines-10020308</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines-10020308</ArticleId><ArticleId IdType="pmc">PMC8875435</ArticleId><ArticleId IdType="pubmed">35214765</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinaki S, Adamopolous S, Deglannnis D, Roussos S, Pavlopoulou ID, Hatzakis A, et al. Immunogenicity of SAVS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients. Amer J Transpl (2021) 21:2913&#x2013;5. 10.1111/ajt.16607</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16607</ArticleId><ArticleId IdType="pmc">PMC8250574</ArticleId><ArticleId IdType="pubmed">33864722</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert PB, Montefiori DC, McDermott A, Fong Y, Benkeser D, Deng W, et al. Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial.. Science (2022) 375:43&#x2013;50. 10.1126/science.abm3425</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm3425</ArticleId><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo SP. Review of COVID-19 Vaccines and Their Evidence in Older Adults. Ann Geriatr Med Res (2021) 25:4&#x2013;9. 10.4235/agmr.21.0011</Citation><ArticleIdList><ArticleId IdType="doi">10.4235/agmr.21.0011</ArticleId><ArticleId IdType="pmc">PMC8024166</ArticleId><ArticleId IdType="pubmed">33550776</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, et al. Reactogenicity and Immunogenicity after a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 in the UK: a Substudy of Two Randomised Controlled Trials (COV001 and COV002).. Lancet (2021) 398:981&#x2013;90. 10.1016/S0140-6736(21)01699-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01699-8</ArticleId><ArticleId IdType="pmc">PMC8409975</ArticleId><ArticleId IdType="pubmed">34480858</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.. N Engl J Med (2021) 385:1244&#x2013;6. 10.1056/NEJMc2111462</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2111462</ArticleId><ArticleId IdType="pmc">PMC8385563</ArticleId><ArticleId IdType="pubmed">34379917</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim Findings from First-Dose Mass COVID-19 Vaccination Roll-Out and COVID-19 Hospital Admissions in Scotland: a National Prospective Cohort Study. Lancet (2021) 397:1646&#x2013;57. 10.1016/S0140-6736(21)00677-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00677-2</ArticleId><ArticleId IdType="pmc">PMC8064669</ArticleId><ArticleId IdType="pubmed">33901420</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal U, Katikireddi SV, McCowan C, Mulholland RH, Azcoaga-Lorenzo A, Amele S, et al. COVID-19 Hospital Admissions and Deaths after BNT162b2 and ChAdOx1 nCoV-19 Vaccinations in 2&#xb7;57 Million People in Scotland (EAVE II): a Prospective Cohort Study. Lancet Respir Med (2021) 9:1439&#x2013;49. 10.1016/S2213-2600(21)00380-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00380-5</ArticleId><ArticleId IdType="pmc">PMC8480963</ArticleId><ArticleId IdType="pubmed">34599903</ArticleId></ArticleIdList></Reference><Reference><Citation>Borobia AM, Carcas AJ, P&#xe9;rez-Olmeda M, Castano L, Bertran MJ, Garcia-Perez J, et al. Immunogenicity and Reactogenicity of BNT162b2 Booster in ChAdOx1-S-Primed Participants (CombiVacS): a Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial. Lancet (2021) 398:121&#x2013;30. 10.1016/S0140-6736(21)01420-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01420-3</ArticleId><ArticleId IdType="pmc">PMC8233007</ArticleId><ArticleId IdType="pubmed">34181880</ArticleId></ArticleIdList></Reference><Reference><Citation>
UK Coronavirus Dashboard. 
https://coronavirus.data.gov.uk/ (Accessed April 10, 2022).</Citation></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med Overseas Ed (2020) 384:403&#x2013;16. 10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak N, Tordesillas L, Cabanillas B. Adverse Rare Events to Vaccines for COVID-19: From Hypersensitivity Reactions to Thrombosis and Thrombocytopenia. Int Rev Immunol (2021) 2021:1&#x2013;10. 10.1080/08830185.2021.1939696</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08830185.2021.1939696</ArticleId><ArticleId IdType="pmc">PMC8290371</ArticleId><ArticleId IdType="pubmed">34251972</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolowska M, Thomas Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, et al. EAACI Statement on the Diagnosis, Management, and Prevention of Severe Allergic Reactions to COVID-19 Vaccines. Allergy (2021) 76:1629&#x2013;39. 10.1111/all.14739</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14739</ArticleId><ArticleId IdType="pmc">PMC8013422</ArticleId><ArticleId IdType="pubmed">33452689</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimabukuro T. Allergic Reactions Including Anaphylaxis after Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021. Am J Transpl (2021) 21:1326&#x2013;31. 10.1111/ajt.16517</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16517</ArticleId><ArticleId IdType="pmc">PMC8013433</ArticleId><ArticleId IdType="pubmed">33641268</ArticleId></ArticleIdList></Reference><Reference><Citation>Arepally GM, Ortel TL. Vaccine-induced Immune Thrombotic Thrombocytopenia: what We Know and Do Not Know.. Blood (2021) 138:293&#x2013;8. 10.1182/blood.2021012152</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021012152</ArticleId><ArticleId IdType="pmc">PMC8172307</ArticleId><ArticleId IdType="pubmed">34323940</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced Immune Thrombotic Thrombocytopenia. Lancet Haematol (2021) -3026(21):e7300306&#x2013;80. 10.1016/S2352-3026(21)00306-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(21)00306-9</ArticleId><ArticleId IdType="pmc">PMC8585488</ArticleId><ArticleId IdType="pubmed">34774202</ArticleId></ArticleIdList></Reference><Reference><Citation>
NICE guideline [NG200]. The National Institute for Health and Care Excellence (NICE) NG200 (2021). https://www.nice.org.uk/guidance/ng200
(Accessed May 12, 2022). </Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and Effectiveness of mRNA BNT162b2 Vaccine against SARS-CoV-2 Infections and COVID-19 Cases, Hospitalisations, and Deaths Following a Nationwide Vaccination Campaign in Israel: an Observational Study Using National Surveillance Data. Lancet (2021) 397:1819&#x2013;29. 10.1016/S0140-6736(21)00947-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00947-8</ArticleId><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>
NIH Research Matters. Vaccines Prevented up to 140,000 COVID-19 Deaths in U.S (2021). https://www.nih.gov/news-events/nih-research-matters/vaccines-prevented-140000-covid-19-deaths-us
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>
Public Health England. COVID-19 Vaccine Surveillance Report Week 38 (2021). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1019992/Vaccine_surveillance_report_-_week_38.pdf
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>
Public Health England. COVID-19 Vaccine Surveillance Report Published (2021). https://www.gov.uk/government/news/covid-19-vaccine-surveillance-report-published
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk Factors and Disease Profile of post-vaccination SARS-CoV-2 Infection in UK Users of the COVID Symptom Study App: a Prospective, Community-Based, Nested, Case-Control Study. Lancet Infect Dis (2022) 22:43&#x2013;55. 10.1016/S1473-3099(21)00460-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Subbarao K. The success of SARS-CoV-2 Vaccines and Challenges Ahead. Cell Host Microbe (2021) 29:1111&#x2013;23. 10.1016/j.chom.2021.06.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.06.016</ArticleId><ArticleId IdType="pmc">PMC8279572</ArticleId><ArticleId IdType="pubmed">34265245</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and Functional Properties of SARS-CoV-2 Spike Protein: Potential Antivirus Drug Development for COVID-19. Acta Pharmacol Sin (2020) 41:1141&#x2013;9. 10.1038/s41401-020-0485-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-020-0485-4</ArticleId><ArticleId IdType="pmc">PMC7396720</ArticleId><ArticleId IdType="pubmed">32747721</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Jackson CB, Mou H, Ojha A, Peng H, Quinlan BD, et al. SARS-CoV-2 Spike-Protein D614G Mutation Increases Virion Spike Density and Infectivity. Nat Commun (2020) 11:6013. 10.1038/s41467-020-19808-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19808-4</ArticleId><ArticleId IdType="pmc">PMC7693302</ArticleId><ArticleId IdType="pubmed">33243994</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama T, Weeraratne D, Snowdon JL, Parida L. Emergence of Drift Variants that May Affect COVID-19 Vaccine Development and Antibody Treatment. Pathogens (2020) 9(5):324. 10.3390/pathogens9050324</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens9050324</ArticleId><ArticleId IdType="pmc">PMC7281497</ArticleId><ArticleId IdType="pubmed">32357545</ArticleId></ArticleIdList></Reference><Reference><Citation>Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell (2020) 182(4):812&#x2013;27. 10.1016/j.cell.2020.06.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.043</ArticleId><ArticleId IdType="pmc">PMC7332439</ArticleId><ArticleId IdType="pubmed">32697968</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut A, Holmes EC, O'Toole &#xc1;, Hill V, McCrone JT, Ruis C, et al. A Dynamic Nomenclature Proposal for SARS-CoV-2 Lineages to Assist Genomic Epidemiology. Nat Microbiol (2020) 5:1403&#x2013;7. 10.1038/s41564-020-0770-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0770-5</ArticleId><ArticleId IdType="pmc">PMC7610519</ArticleId><ArticleId IdType="pubmed">32669681</ArticleId></ArticleIdList></Reference><Reference><Citation>
Department for Business, Energy &amp; Industrial Strategy, Department of Health and Social Care, Government Office for Science, Public Health England, Medical Research Council, and The Rt Hon Alok Sharma MP. UK launches whole genome sequence alliance to map spread of coronavirus (2020). 
https://www.gov.uk/government/news/uk-launches-whole-genome-sequence-alliance-to-map-spread-of-coronavirus (Accessed May 12, 2022). </Citation></Reference><Reference><Citation>Hodcroft EB, Zuber M, Nadeau S, Vaughan TG, Crawford KHD, Althaus CL, et al. Spread of a SARS-CoV-2 Variant through Europe in the Summer of 2020. Nature (2021) 595:707&#x2013;12. 10.1038/s41586-021-03677-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03677-y</ArticleId><ArticleId IdType="pubmed">34098568</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubey A, Choudhary S, Kumar P, Tomar S. Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. Curr Microbiol (2021) 79(1):20. 10.1007/s00284-021-02724-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00284-021-02724-1</ArticleId><ArticleId IdType="pmc">PMC8669229</ArticleId><ArticleId IdType="pubmed">34905108</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman R, Patel KJ, Ranjan K. COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. Biomolecules (2021) 11:993. 10.3390/biom11070993</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11070993</ArticleId><ArticleId IdType="pmc">PMC8301790</ArticleId><ArticleId IdType="pubmed">34356617</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung K, Shum MH, Leung GM, Lam TT, Wu JT. Early Transmissibility Assessment of the N501Y Mutant Strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Eurosurveillance (2021) 26:2002106. 10.2807/1560-7917.es.2020.26.1.2002106</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.es.2020.26.1.2002106</ArticleId><ArticleId IdType="pmc">PMC7791602</ArticleId><ArticleId IdType="pubmed">33413740</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The Biological and Clinical Significance of Emerging SARS-CoV-2 Variants. Nat Rev Genet (2021) 22:757&#x2013;73. 10.1038/s41576-021-00408-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-021-00408-x</ArticleId><ArticleId IdType="pmc">PMC8447121</ArticleId><ArticleId IdType="pubmed">34535792</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby T. New Variant of SARS-CoV-2 in UK Causes Surge of COVID-19. Lancet Respir Med (2021) 9:e20&#x2013;e21. 10.1016/S2213-2600(21)00005-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00005-9</ArticleId><ArticleId IdType="pmc">PMC7784534</ArticleId><ArticleId IdType="pubmed">33417829</ArticleId></ArticleIdList></Reference><Reference><Citation>Vohringer HS, Sanderson T, Sinnott M, De Maio N, Nguyen T, Goater R, et al. Genomic Reconstruction of the SARS-CoV-2 Epidemic in England. Nature (2021) 600:506&#x2013;11. 10.1038/s41586-021-04069-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04069-y</ArticleId><ArticleId IdType="pmc">PMC8674138</ArticleId><ArticleId IdType="pubmed">34649268</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Detection of a SARS-CoV-2 Variant of Concern in South Africa. Nature (2021) 592:438&#x2013;43. 10.1038/s41586-021-03402-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03402-9</ArticleId><ArticleId IdType="pubmed">33690265</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DS, Mishra S, et al. Genomics and Epidemiology of the P.1 SARS-CoV-2 Lineage in Manaus, Brazil. Science (2021) 372:815&#x2013;21. 10.1126/science.abh2644</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh2644</ArticleId><ArticleId IdType="pmc">PMC8139423</ArticleId><ArticleId IdType="pubmed">33853970</ArticleId></ArticleIdList></Reference><Reference><Citation>
Public Health England. SARS-CoV-2 Technical Briefing 19 (2021). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1005517/Technical_Briefing_19.pdf
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>
UK Health Security Agency. SARS-CoV-2 Technical Briefing 32 (2021). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1042688/RA_Technical_Briefing_32_DRAFT_17_December_2021_2021_12_17.pdf
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>
Cov-Lineages. Pango Lineages: Latest Epidemiological Lineages of SARS-CoV-2 (2021). https://cov-lineages.org/global_report_B.1.617.2.html
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>Callaway E. Delta Coronavirus Variant: Scientists Brace for Impact. Nature (2021) 595:17&#x2013;8. 10.1038/d41586-021-01696-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-01696-3</ArticleId><ArticleId IdType="pubmed">34158664</ArticleId></ArticleIdList></Reference><Reference><Citation>Burki TK. Omicron Variant and Booster COVID-19 Vaccines. Lancet Respir Med (2021) 10:e17. 10.1016/S2213-2600(21)00559-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00559-2</ArticleId><ArticleId IdType="pmc">PMC8683118</ArticleId><ArticleId IdType="pubmed">34929158</ArticleId></ArticleIdList></Reference><Reference><Citation>Twohig KA, Nyberg T, Zaiai A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital Admission and Emergency Care Attendance Risk for SARS-CoV-2 delta (B.1.617.2) Compared with Alpha (B.1.1.7) Variants of Concern: a Cohort Study. Lancet Infect Dis (2022) 22:35&#x2013;42. 10.1016/S1473-3099(21)00475-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00475-8</ArticleId><ArticleId IdType="pmc">PMC8397301</ArticleId><ArticleId IdType="pubmed">34461056</ArticleId></ArticleIdList></Reference><Reference><Citation>
UK Health Security Agency. SARS-CoV-2 Technical Briefing (2021). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1036501/Technical_Briefing_29_published_26_November_2021.pdf
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>Chen J, Wang R, Gilby NB, Wei GW. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. J Chem Inf Model (2022) 62:412&#x2013;22. 10.1021/acs.jcim.1c01451</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.1c01451</ArticleId><ArticleId IdType="pmc">PMC8751645</ArticleId><ArticleId IdType="pubmed">34989238</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhang L, Li Q, Li T, Liu S, Cui Q, et al. The Significant Immune Escape of Pseudotyped SARS-CoV-2 Variant Omicron. Emerg Microbes Infect (2022) 11:1&#x2013;5. 10.1080/22221751.2021.2017757</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2017757</ArticleId><ArticleId IdType="pmc">PMC8725892</ArticleId><ArticleId IdType="pubmed">34890524</ArticleId></ArticleIdList></Reference><Reference><Citation>
UK Health Security Agency. SARS-CoV-2 Technical Briefing 30 (2021). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1038404/Technical_Briefing_30.pdf
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 Variants, Spike Mutations and Immune Escape. Nat Rev Microbiol (2021) 19:409&#x2013;24. 10.1038/s41579-021-00573-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito K, Piantham C, Nishiura H. Relative Instantaneous Reproduction Number of Omicron SARS-CoV-2 Variant with Respect to the Delta Variant in Denmark. J Med Virol (2021) 94:2265&#x2013;8. 10.1002/jmv.27560</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27560</ArticleId><ArticleId IdType="pmc">PMC9015237</ArticleId><ArticleId IdType="pubmed">34967453</ArticleId></ArticleIdList></Reference><Reference><Citation>
UK Health Security Agency. Technical Briefing 33: Underlying Data (2021). 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1043695/variants-of-concern-technical-briefing-33-data-england-23-december-2021.ods (Accessed May 12, 2022). </Citation></Reference><Reference><Citation>
UK Health Security Agency. Omicron Daily Overview (2021). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1044331/20211230_OS__Omicron_Daily_Overview.pdf
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, et al. Reduced Neutralisation of SARS-CoV-2 Omicron B.1.1.529 Variant by post-immunisation Serum. Lancet (2021) 399:234&#x2013;6. 10.1016/S0140-6736(21)02844-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02844-0</ArticleId><ArticleId IdType="pmc">PMC8687667</ArticleId><ArticleId IdType="pubmed">34942101</ArticleId></ArticleIdList></Reference><Reference><Citation>
UK Health Security Agency. SARS-CoV-2 Variants of Concern and Variants under Investigation in England (2021). Technical briefing 31 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1042367/technical_briefing-31-10-december-2021.pdf (Accessed May 12, 2022).
</Citation></Reference><Reference><Citation>
UK Health Security Agency. SARS-CoV-2 Variants of Concern and Variants under Investigation in England (2021). Technical briefing 32: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1042688/RA_Technical_Briefing_32_DRAFT_17_December_2021_2021_12_17.pdf (Accessed May 12, 2022).
</Citation></Reference><Reference><Citation>
UK Health Security Agency. SARS-CoV-2 Variants of Concern and Variants under Investigation in England (2022). Technical briefing 36: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1056487/Technical-Briefing-36-22.02.22.pdf (Accessed May 12, 2022).
</Citation></Reference><Reference><Citation>
UK Health Security Agency. SARS-CoV-2 Variants of Concern and Variants under Investigation in England (2022). Technical briefing 39 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINAL.pdf (Accessed May 12, 2022).
</Citation></Reference><Reference><Citation>Fonager J, Bennedb&#xe6;k M, Bager P, Wohlfahrt J, Ellegaard KM, Ingham AC, et al. Molecular Epidemiology of the SARS-CoV-2 Variant Omicron BA.2 Sub-lineage in Denmark, 29 November 2021 to 2 January 2022. Euro Surveill (2022) 27(10):2200181. 10.2807/1560-7917.ES.2022.27.10.2200181</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.10.2200181</ArticleId><ArticleId IdType="pmc">PMC8915403</ArticleId><ArticleId IdType="pubmed">35272746</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret P, Hoang VT, Jimeno MT, Lagier JC, Rossi P, Fournier PE, et al. Severity of the First 207 Infections with the SARS-CoV-2 Omicron BA.2 Variant, in Marseille, France, December, 2021-February, 2022. J Med Virol (2022) 94:3494&#x2013;7. 10.1002/jmv.27760</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27760</ArticleId><ArticleId IdType="pmc">PMC9088598</ArticleId><ArticleId IdType="pubmed">35365865</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruel T, Hadjadj J, Maes P, Planas D, Seve A, Staropoli I, et al. Serum Neutralization of SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 in Patients Receiving Monoclonal Antibodies.. Nat Med (2022) 28:1297&#x2013;302. 10.1038/s41591-022-01792-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01792-5</ArticleId><ArticleId IdType="pubmed">35322239</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen RM, Bang LL, Madsen LW, Sydenham TV, Johansen IS, Jensen TG, et al. Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination.. Emerg Infect Dis (2022) 28(6):1274&#x2013;5. 10.3201/eid2806.220503</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2806.220503</ArticleId><ArticleId IdType="pmc">PMC9155893</ArticleId><ArticleId IdType="pubmed">35356875</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LL, Chu AW, Zhang RR, Hung IFN, To KKW. Serum Neutralisation of the SARS-CoV-2 Omicron Sublineage BA.2. Lancet Microbe (2022) 3:e404. 10.1016/S2666-5247(22)00060-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00060-X</ArticleId><ArticleId IdType="pmc">PMC8959473</ArticleId><ArticleId IdType="pubmed">35373159</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia X. Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design. Viruses (2021) 13:109. 10.3390/v13010109</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13010109</ArticleId><ArticleId IdType="pmc">PMC7829931</ArticleId><ArticleId IdType="pubmed">33466921</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez CE, Perdiguero B, Esteban M. Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/covid-19. Vaccines (2021) 9:243. 10.3390/vaccines9030243</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9030243</ArticleId><ArticleId IdType="pmc">PMC7999234</ArticleId><ArticleId IdType="pubmed">33799505</ArticleId></ArticleIdList></Reference><Reference><Citation>Noori M, Nejadghaderi SA, Arshi S, Carson-Chahhoud K, Ansarin K, Kolahi AA, et al. Potency of BNT162b2 and mRNA-1273 Vaccine-Induced Neutralizing Antibodies against Severe Acute Respiratory Syndrome-CoV-2 Variants of Concern: A Systematic Review of In Vitro Studies. Rev Med Virol (2021) 32:e2277. 10.1002/rmv.2277</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2277</ArticleId><ArticleId IdType="pmc">PMC8420542</ArticleId><ArticleId IdType="pubmed">34286893</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Flores D, Zepeda-Cervantes J, Cruz-Res&#xe9;ndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L. SARS-Cov-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. Front Immunol (2021) 12:701501. 10.3389/fimmu.2021.701501</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.701501</ArticleId><ArticleId IdType="pmc">PMC8311925</ArticleId><ArticleId IdType="pubmed">34322129</ArticleId></ArticleIdList></Reference><Reference><Citation>Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 Vaccine Effort: Viruses, Vaccines and Variants versus Efficacy, Effectiveness and Escape. Nat Rev Immunol (2021) 21:626&#x2013;36. 10.1038/s41577-021-00592-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00592-1</ArticleId><ArticleId IdType="pmc">PMC8351583</ArticleId><ArticleId IdType="pubmed">34373623</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan R, Shawa I, De La Torre I, Pustizzi JM, Haustrup N, Patel DR, et al. A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2. Infect Dis Ther (2021) 10:1933&#x2013;47. 10.1007/s40121-021-00515-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-021-00515-6</ArticleId><ArticleId IdType="pmc">PMC8353431</ArticleId><ArticleId IdType="pubmed">34374951</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Cai C, Grifoni A, Muller TR, Niessl J, Olofsson A, et al. Ancestral SARS-CoV-2-specific T Cells Cross-Recognize the Omicron Variant. Nat Med (2022) 28:472&#x2013;6. 10.1038/s41591-022-01700-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01700-x</ArticleId><ArticleId IdType="pmc">PMC8938268</ArticleId><ArticleId IdType="pubmed">35042228</ArticleId></ArticleIdList></Reference><Reference><Citation>
UK Health Security Agency. SARS-CoV-2 Variants of Concern and Variants Under Investigation in England (2021). Technical Briefing 28. 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1033101/Technical_Briefing_28_12_Nov_2021.pdf (Accessed May 12, 2022). </Citation></Reference><Reference><Citation>Yelin D, Margalit I, Yahav D, Runold M, Bruchfeld J. Long COVID-19 &#x2013; It&#x2019;s Not over until? Clin Microbiol Infect (2021) 27:506&#x2013;8. 10.1016/j.cmi.2020.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.12.001</ArticleId><ArticleId IdType="pmc">PMC7832095</ArticleId><ArticleId IdType="pubmed">33316400</ArticleId></ArticleIdList></Reference><Reference><Citation>Korompoki E, Gavriatopoulou M, Hicklen RS, Ntanasis-Stathopoulos I, Kastritis E, Fotiou D, et al. Epidemiology and Organ Specific Sequelae of post-acute COVID19: A Narrative Review. J Infect (2021) 83:1&#x2013;16. 10.1016/j.jinf.2021.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.05.004</ArticleId><ArticleId IdType="pmc">PMC8118709</ArticleId><ArticleId IdType="pubmed">33992686</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-Acute COVID-19 Syndrome. Nat Med (2021) 27:601&#x2013;15. 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>
NICE NG188. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19 (2022). https://www.nice.org.uk/guidance/ng188. </Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A Clinical Case Definition of post-COVID-19 Condition by a Delphi Consensus. Lancet Infect Dis (2021) 22:E102&#x2013;E107. 10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings G, Monaghan A, Xue F, Mockler D, Romero-Ortuno R. A Systematic Review of Persistent Symptoms and Residual Abnormal Functioning Following Acute COVID-19: Ongoing Symptomatic Phase vs. Post-COVID-19 Syndrome. J Clin Med (2021) 10:5913. 10.3390/jcm10245913</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10245913</ArticleId><ArticleId IdType="pmc">PMC8708187</ArticleId><ArticleId IdType="pubmed">34945213</ArticleId></ArticleIdList></Reference><Reference><Citation>Research Accessibility Team. The Microvascular Hypothesis Underlying Neurologic Manifestations of Long COVID-19 and Possible Therapeutic Strategies. Cardiovasc Endocrinol Metab (2021) 10:193&#x2013;203. 10.1097/XCE.0000000000000253</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/XCE.0000000000000253</ArticleId><ArticleId IdType="pmc">PMC8575441</ArticleId><ArticleId IdType="pubmed">34765889</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological Dysfunction Persists for 8 Months Following Initial Mild-To-Moderate SARS-CoV-2 Infection. Nat Immunol (2022) 23:210&#x2013;6. 10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Poudel AN, Zhu S, Cooper N, Roderick P, Alwan N, Tarrant C, et al. Impact of Covid-19 on Health-Related Quality of Life of Patients: A Structured Review. PLoS One (2021) 16:e0259164. 10.1371/journal.pone.0259164</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0259164</ArticleId><ArticleId IdType="pmc">PMC8553121</ArticleId><ArticleId IdType="pubmed">34710173</ArticleId></ArticleIdList></Reference><Reference><Citation>Camporota L, Cronin JN, Busana M, Gattinoni L, Formenti F. Pathophysiology of Coronavirus-19 Disease Acute Lung Injury. Curr Opin Crit Care (2022) 28(1):9&#x2013;16. 10.1097/mcc.0000000000000911</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/mcc.0000000000000911</ArticleId><ArticleId IdType="pmc">PMC8711311</ArticleId><ArticleId IdType="pubmed">34907979</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambardar SR, Hightower SL, Huprikar NA, Chung KK, Singhal A, Collen JF. Post-COVID-19 Pulmonary Fibrosis: Novel Sequelae of the Current Pandemic. J Clin Med (2021) 10:2452. 10.3390/jcm10112452</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10112452</ArticleId><ArticleId IdType="pmc">PMC8199255</ArticleId><ArticleId IdType="pubmed">34205928</ArticleId></ArticleIdList></Reference><Reference><Citation>John AE, Joseph C, Jenkins G, Tatler AL. COVID&#x2010;19 and Pulmonary Fibrosis: a Potential Role for Lung Epithelial Cells and Fibroblasts. Immunol Rev (2021) 302:228&#x2013;40. 10.1111/imr.12977</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12977</ArticleId><ArticleId IdType="pmc">PMC8237078</ArticleId><ArticleId IdType="pubmed">34028807</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, et al. 3-month, 6-month, 9-month, and 12-month Respiratory Outcomes in Patients Following COVID-19-Related Hospitalisation: a Prospective Study. Lancet Respir Med (2021) 9:P747&#x2013;754. 10.1016/S2213-2600(21)00174-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00174-0</ArticleId><ArticleId IdType="pmc">PMC8099316</ArticleId><ArticleId IdType="pubmed">33964245</ArticleId></ArticleIdList></Reference><Reference><Citation>Safont B, Tarraso J, Rodriguez-Borja E, Fernandez-Fabrellas E, Sancho-Chust JN, Molina V, et al. Lung Function, Radiological Findings and Biomarkers of Fibrogenesis in a Cohort of COVID-19 Patients Six Months after Hospital Discharge. Arch Bronconeumol (2021) 58:142&#x2013;9. 10.1016/j.arbres.2021.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arbres.2021.08.014</ArticleId><ArticleId IdType="pmc">PMC8414844</ArticleId><ArticleId IdType="pubmed">34497426</ArticleId></ArticleIdList></Reference><Reference><Citation>Robey RC, Kemp K, Hayton P, Mudawi D, Wang R, Greaves M, et al. Pulmonary Sequelae at 4 Months after COVID-19 Infection: A Single-Centre Experience of a COVID Follow-Up Service. Adv Ther (2021) 38:4505&#x2013;19. 10.1007/s12325-021-01833-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-021-01833-4</ArticleId><ArticleId IdType="pmc">PMC8286847</ArticleId><ArticleId IdType="pubmed">34278556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigami J, Kou M, Ding N, Matsushita K. Cardiovascular Disease and Coronavirus Disease 2019:Epidemiology, Management and Prevention. Curr Epidemiol Rep (2021) 8:1&#x2013;8. 10.1007/s40471-020-00261-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40471-020-00261-2</ArticleId><ArticleId IdType="pmc">PMC7778411</ArticleId><ArticleId IdType="pubmed">33425654</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijmes FS, Thavendiranathan P, Udell JA, Seidman MA, Hanneman K. Cardiac MRI. Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination. Radiol Cardiothorac Imaging (2021) 3:e210252. 10.1148/ryct.210252</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/ryct.210252</ArticleId><ArticleId IdType="pmc">PMC8686006</ArticleId><ArticleId IdType="pubmed">34934954</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Zhang B, Zhou Q, Yang W, Xu J, Liu T, et al. The Prognostic Value of Myocardial Injury in COVID-19 Patients and Associated Characteristics. Immun Inflamm Dis (2021) 9:1358&#x2013;69. 10.1002/iid3.484</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.484</ArticleId><ArticleId IdType="pmc">PMC8427070</ArticleId><ArticleId IdType="pubmed">34240818</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Urbanus RT, Ten Cate H, de Groot PG, de Laat B, Heemskerk JWM, et al. Platelet Activation Mechanisms and Consequences of Immune Thrombocytopenia. Cells (2021) 10:3386. 10.3390/cells10123386</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10123386</ArticleId><ArticleId IdType="pmc">PMC8699996</ArticleId><ArticleId IdType="pubmed">34943895</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandelwal G, Ray A, Sethi S, Harikrishnan HK, Khandelwal C, Sadasivam B. COVID-19 and Thrombotic Complications &#x2013; the Role of Anticoagulants, Antiplatelets and Thrombolytics. J Fam Med Prim Care (2021) 10:3561&#x2013;7. 10.4103/jfmpc.jfmpc_1297_20</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jfmpc.jfmpc_1297_20</ArticleId><ArticleId IdType="pmc">PMC8653484</ArticleId><ArticleId IdType="pubmed">34934647</ArticleId></ArticleIdList></Reference><Reference><Citation>Roychoudhury S, Das A, Sengupta P, Ahmed ABF, Dutta S, Choudhury AP, et al. Viral Pandemics of the Last Four Decades: Pathophysiology, Health Impacts and Perspectives. Int J Environ Res Public Health (2020) 17(24):9411. 10.3390/ijerph17249411</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17249411</ArticleId><ArticleId IdType="pmc">PMC7765415</ArticleId><ArticleId IdType="pubmed">33333995</ArticleId></ArticleIdList></Reference><Reference><Citation>Unwin RJ. The 1918 Influenza Pandemic: Back to the Future? Kidney Blood Press Res (2021) 46:639&#x2013;46. 10.1159/000519288</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000519288</ArticleId><ArticleId IdType="pubmed">34662882</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarpa R, Caso F, Costa L, Passavanti S, Vitale MG, Trojaniello C, et al. May the Analysis of 1918 Influenza Pandemic Give Hints to Image the Possible Magnitude of corona Virus Disease-2019 (COVID-19)? J Transl Med (2020) 18:489. 10.1186/s12967-020-02673-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02673-6</ArticleId><ArticleId IdType="pmc">PMC7753514</ArticleId><ArticleId IdType="pubmed">33353549</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2016 Causes of Death Collaborators. Global, Regional and National Age-Sex Specific Mortality for 264 Causes of Death 1980-2016: a Systematic Analysis for the Global burden of Disease Study 2016. Lancet (2017) 390:1151&#x2013;210. 10.1016/S0140-6736(17)32152-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)32152-9</ArticleId><ArticleId IdType="pmc">PMC5605883</ArticleId><ArticleId IdType="pubmed">28919116</ArticleId></ArticleIdList></Reference><Reference><Citation>
UK Office for National Statistics. UK Office for National Statistics Figures on Deaths Due to Specific Causes (2022). https://www.nomisweb.co.uk/home/Search?context=&amp;term=mortality
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>Strongman H, Carreira H, De Stavola BL, Bhaskaran K, Leon DA. Factors Associated with Excess All-Cause Mortality in the First Wave of the COVID-19 Pandemic in the UK: A Time Series Analysis Using the Clinical Practice Research Datalink.. PLOS Med (2022) 19(1):e1003870. 10.1371/journal.pmed.1003870</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003870</ArticleId><ArticleId IdType="pmc">PMC8735664</ArticleId><ArticleId IdType="pubmed">34990450</ArticleId></ArticleIdList></Reference><Reference><Citation>
Office for National Statistics. Deaths of Those Under 60 From COVID-19 With No Co-Morbidities and Mortality Rates in 2020 (2021). 
https://www.ons.gov.uk/aboutus/transparencyandgovernance/freedomofinformationfoi/deathsofthoseunder60fromcovid19withnocomorbiditiesandmortalityratesin2020 (Accessed May 12, 2022). </Citation></Reference><Reference><Citation>Oboza P, Ogarek N, Olszanecka-Glinianowicz M, Kocelak P. COVID-19 and Obesity: the Confrontation of Two Pandemics. Eur Rev Med Pharmacol Sci (2022) 26:695&#x2013;709. 10.26355/eurrev_202201_27896</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202201_27896</ArticleId><ArticleId IdType="pubmed">35113445</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates T, Summerfield A, Razieh C, Banerjee A, Chudasama Y, Davies MJ, et al. A Population-Based Cohort Study of Obesity, Ethnicity and COVID-19 Mortality in 12.6 Million Adults in England.. Nat Commun (2022) 13(1):624. 10.1038/s41467-022-28248-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28248-1</ArticleId><ArticleId IdType="pmc">PMC8810846</ArticleId><ArticleId IdType="pubmed">35110546</ArticleId></ArticleIdList></Reference><Reference><Citation>
Office for National Statistics. Deaths registered weekly in England and Wales, provisional (2022). https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/weeklyprovisionalfiguresondeathsregisteredinenglandandwales
</Citation></Reference><Reference><Citation>Castiello T, Georgiopoulos G, Finocchiaro G, Claudia M, Gianatti A, Delialis D, et al. COVID-19 and Myocarditis: a Systematic Review and Overview of Current Challenges. Heart Fail Rev (2022) 27:251&#x2013;61. 10.1007/s10741-021-10087-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-021-10087-9</ArticleId><ArticleId IdType="pmc">PMC7988375</ArticleId><ArticleId IdType="pubmed">33761041</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q, Zheng B, Daines L, Sheikh A. Long Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on post-COVID Symptoms. Pathogens (2022) 11(2):269. 10.3390/pathogens11020269</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>
UK Health Security Agency. Weekly National Influenza and COVID-19 Surveillance Report Week 2 Report (Up to Week 1 Data) (2022). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1046284/weekly-flu-and-covid-19-report-week-2-2022.pdf
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>Stout S, Murphy H, Pandya A, Yeh HW, Portnoy J. The Effect of Coronavirus Disease 2019 on Asthma Visits.. Ann Allergy Asthma Immunol (2022) 128(22):59400048&#x2013;5955. 10.1016/j.anai.2022.01.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anai.2022.01.027</ArticleId><ArticleId IdType="pmc">PMC8801266</ArticleId><ArticleId IdType="pubmed">35101645</ArticleId></ArticleIdList></Reference><Reference><Citation>
NHS Digital. National Diabetes Audit Programme (2011). https://digital.nhs.uk/data-and-information/clinical-audits-and-registries/national-diabetes-audit
(Accessed May 12, 2022). </Citation></Reference><Reference><Citation>Dupraz J, Le Pogam MA, Peytremann-Bridevaux I. Early Impact of the COVID-19 Pandemic on In-Person Outpatient Care Utilisation: a Rapid Review. BMJ Open (2022) 12(3):e056086. 10.1136/bmjopen-2021-056086</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-056086</ArticleId><ArticleId IdType="pmc">PMC8895419</ArticleId><ArticleId IdType="pubmed">35241471</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakhshandeh B, Jahanafrooz Z, Abbasi A, Goli MB, Sadeghi M, Mottaqi MS, et al. Mutations in SARS-CoV-2; Consequences in Structure, Function, and Pathogenicity of the Virus. Microb Pathog (2021) 154:104831. 10.1016/j.micpath.2021.104831</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2021.104831</ArticleId><ArticleId IdType="pmc">PMC7955574</ArticleId><ArticleId IdType="pubmed">33727169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wabalo EK, Dubiwak AD, Senbetu MW, Gizaw TS. Effect of Genomic and Amino Acid Sequence Mutation on Virulence and Therapeutic Target of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS COV-2). Infect Drug Resist (2021) 14:2187&#x2013;92. 10.2147/IDR.S307374</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S307374</ArticleId><ArticleId IdType="pmc">PMC8214021</ArticleId><ArticleId IdType="pubmed">34163183</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, et al. SARS-CoV-2 Omicron Variant Replication in Human Bronchus and Lung Ex Vivo. Nature (2022) 603:715&#x2013;20. 10.1038/s41586-022-04479-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04479-6</ArticleId><ArticleId IdType="pubmed">35104836</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacobucci G. Covid-19: Government Plans to Remove All Remaining Restrictions in England a Month Early. BMJ (2022) 376:o355. 10.1136/bmj.o355</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o355</ArticleId><ArticleId IdType="pubmed">35140071</ArticleId></ArticleIdList></Reference><Reference><Citation>
Office for National Statistics. Coronavirus (COVID-19) Infection Survey technical article Coronavirus (COVID-19) Infection Survey technical article: waves and lags of COVID-19 in England, June 2021 (2021). https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsurveytechnicalarticle/wavesandlagsofcovid19inenglandjune2021
</Citation></Reference><Reference><Citation>Schultze A, Nightingale E, Evans D, Hulme W, Rosello A, Bates C, et al. Mortality Among Care Home Residents in England during the First and Second Waves of the COVID-19 Pandemic: an Observational Study of 4.3 Million Adults over the Age of 65. The Lancet Reg Health - Europe (2022) 14:100295. 10.1016/j.lanepe.2021.100295</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100295</ArticleId><ArticleId IdType="pmc">PMC8743167</ArticleId><ArticleId IdType="pubmed">35036983</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirzaei R, Mahdavi F, Badrzdeh F, Hosseini-Fard SR, Heidary M, Jeda AS, et al. The Emerging Role of microRNAs in the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.. Int Immunopharmacol (2021) 90:107204. 10.1016/j.intimp.2020.107204</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.107204</ArticleId><ArticleId IdType="pmc">PMC7664359</ArticleId><ArticleId IdType="pubmed">33221169</ArticleId></ArticleIdList></Reference><Reference><Citation>Bautista-Becerril B, P&#xe9;rez-Dimas G, Sommerhalder-Nava PC, et al. miRNAs, from Evolutionary Junk to Possible Prognostic Markers and Therapeutic Targets in COVID-19. Viruses (2021) 14(1):41. 10.3390/v14010041</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14010041</ArticleId><ArticleId IdType="pmc">PMC8781105</ArticleId><ArticleId IdType="pubmed">35062245</ArticleId></ArticleIdList></Reference><Reference><Citation>Strongman H, Carreira H, De Stavola BL, Bhaskaran K, Leon DA. Factors Associated with Excess All-Cause Mortality in the First Wave of the COVID-19 Pandemic in the UK: A Time Series Analysis Using the Clinical Practice Research Datalink. Plos Med (2022) 19(1):e1003870. 10.1371/journal.pmed.1003870</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003870</ArticleId><ArticleId IdType="pmc">PMC8735664</ArticleId><ArticleId IdType="pubmed">34990450</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: Outbreak Could Last until spring 2021 and see7.9 Million Hospitalised in the UK. BMJ (2020) 368:m1071. 10.1136/bmj.m1071</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1071</ArticleId><ArticleId IdType="pubmed">32179567</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: UK Starts Social Distancing after New Model Points to 260 000 Potential Deaths. BMJ (2020) 368:m1089. 10.1136/bmj.m1089</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1089</ArticleId><ArticleId IdType="pubmed">32184205</ArticleId></ArticleIdList></Reference><Reference><Citation>del Rio C, Malani PN. COVID-19 in 2020 &#x2013; The Beginning of the End or the End of the Beginning? J Amer Med Assoc (2022) 327(24):2389&#x2013;90. 10.1001/jama.2022.9655</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.9655</ArticleId><ArticleId IdType="pubmed">35622357</ArticleId></ArticleIdList></Reference><Reference><Citation>
UK Health Security Agency. SARS-CoV-2 Variants of Concern and Variants Under Investigation. Technical Briefing 43. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1085404/Technical-Briefing-43.pdf (Accessed June 28, 2022)
</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>